Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Highlights the need for consensus on assessing kidney function in acute decompensated heart failure to improve long-term outcomes.
Annual hospitalizations for acute decompensated heart failure (ADHF) exceed 1.2 million in both the United States and Europe and are a powerful predictor of future readmissions and death.1 Therefore, optimal and sustained decongestion of patients in ADHF is essential to reduce recidivism and improve outcomes. Developing therapeutics, both drugs and devices, for ADHF has proven to be particularly difficult, with many trials focusing on short-term benefits. Drugs for ADHF can be approved on the basis of alleviating symptoms and improving quality of life without affecting survival or hospitalization.
No takes yet. Share an insight, caveat, or question.
Cavagna et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: